朗姿股份(002612.SZ)：上半年淨利8912.53萬元 同比降20.18%
格隆匯8月23日丨朗姿股份(002612.SZ)披露2019年半年度報告，報告期內公司實現營業收入13.98億元，同比增長7.72%；歸屬於上市公司股東的淨利潤8912.53萬元，同比下降20.18%；經營活動現金淨流入1.10億元，同比下降19.07%；基本每股收益0.2228元，加權平均淨資產收益率3.16%。
報告期內，女裝業務緊跟大眾消費需求和消費方式的變化，精準定位產品主要消費羣體，積極地進行產品升級調整，設計創新，增加天然環保、舒適面料的使用，以“知性、優雅、時尚”的國際化品牌定位，以及幫助客户實現“年輕、時尚、品質、舒適愉悦的生活方式”的經營理念，輔以“後台精細，前台精緻”的服務方式，打造品牌特色，持續提升品牌影響力。
作為韓國國民品牌，公司嬰童業務阿卡邦的主體在韓國，公司收購後專門設立了中國的運營團隊，並將該品牌在中國的經營進行了有力的改善和市場的廣泛佈局。報告期內，阿卡邦韓國通過對低效店鋪的關停和業務模式的調整，銷售收入和經營業績均有所提升；阿卡邦中國完成了由韓國和中國設計師組成的設計團隊的組建，配合由年輕人組成的國內的產品團隊，從線上、線下滿足國內消費者對嬰童產品時尚、舒適的追求，下一步，公司繼續提高銷售終端的開設速度，將終端的佈局自北京、杭州、成都向國內重點城市延伸。
報告期內，公司三大醫美品牌“米蘭柏羽”、“高一生”和“晶膚醫美”各自憑藉自身的優勢，逐步形成了資源上的協同，業績逐步增長，公司通過醫美業務統一管理平台“朗姿醫療”，建立了完整、合規的標準管理制度，通過標準化的流程控制，實現醫美服務的質量控制和服務規範化，人才隊伍建設穩定，為公司醫美業務的進一步發展特別是跨區域連鎖擴張創造了良好的條件。為深化公司對醫美業務的戰略部署，運用資本市場平台整合已有的醫療領域資源，提升上市公司盈利能力，公司於報告期內籌劃並實施了通過發行股份購買資產的方式以實現對朗姿醫管少數股權的收購，達到了對朗姿醫美業務管理平台“朗姿醫療”的100%控股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
